Citations

Clear

7552 citation(s) found for "Ku, Matthew".

DNA Immunotherapy for Recurrent Respiratory Papillomatosis (RRP): Phase 1/2 study assessing efficacy, safety, and immunogenicity of INO-3107
Morrow, Matthew P. , Gillespie, Elisabeth, Sylvester, Albert J. , Belafsky, Peter C. , Best, Simon R. , Friedman, Aaron D. , Pransky, Seth M. , Tan, Grace , Wisotsky, Sadie, Reuschel, Emma L. , Reed, Katherine , Dallas, Michael, Skolnik, Jeffrey , Morrow, Matthew P. , Klein, Adam M. , Lott, David G. , Mau, Ted , Paniello, Randal C. , Saba, Nabil F. , Tan, Grace S., Marcus, Sarah A. , Weiner, David B , Dallas, Michael J., Skolnik, Jeffrey M.

Mayo Clinic

No container title available | September 18, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4770252/v1 Get It

Abstract Recurrent respiratory papillomatosis (RRP) is a debilitating chronic disease of the airway caused by Human Papillomavirus (HPV). Here we describe the efficacy, safety, and immunogenicity from a Phase 1/2 trial of INO-3107, a DNA immunotherapy designed to elicit T-cell responses against HPV-6 and HPV-11, in adults with RRP (NCT04398433). Thirty-two eligible patients with HPV-6 and/or HPV-11 RRP, who required ≥2 surgical interventions in the year preceding dosing, were administered 4 doses of INO-3107 by intramuscular (IM) injection followed by electroporation (EP). The primary endpoint was safety and tolerability. Efficacy and immunology endpoints included the frequency of surgical interventions in the year following the first dose of INO-3107 and assessment of immune responses. The majority (26/32; 81%) of patients experienced a reduction in the number of surgeries in the year following initiation of treatment with INO-3107, when compared with the year prior. Peripheral blood assessments revealed HPV-6 and HPV-11 antigen-specific T-cell induction, inclusive of cytolytic CD8+ T-cells. RNA sequencing identified the presence of an inflammatory response in patient papillomas after treatment with INO-3107, inclusive of cytolytic CD8+ T-cell signatures. T-cell receptor sequencing revealed emergent T-cell clones in the blood and assessment of airway tissue confirmed trafficking of these clones to papillomas, which was associated with clinical benefit. Treatment was well tolerated, with 13/32 (41%) patients reporting a treatment-related adverse event (AE), all of which were low-grade. INO-3107 provides clinical benefit to adults with HPV-6 and/or HPV-11 associated RRP, is well tolerated, and generates an antigen-specific immune response against HPV. Importantly, treatment-induced peripheral T-cell responses traffick to airway tissue and are associated with clinical response, consistent with the proposed mechanism of action.
Best Practices in Telecritical Care: Expert Consensus Recommendations From the Telecritical Care Collaborative Network
Scott, Benjamin K. , Singh, Jaspal , Hravnak, Marilyn , Everhart, Sonia , Armaignac, Donna Lee , Davis, Theresa, Goede, Matthew R., Haranath, Sai Praveen , Kordik, Christina, Pappas, Peter A., Patel, S. , Rincon, Teresa , Scruth, Elizabeth , Subramanian, Sanjay , Villanueva, Israel, Williams, Lisa-Mae , Wilson, Rodney, Pamplin, Jeremy , Laudański, Krzysztof

Mayo Clinic

Critical Care Medicine | September 17, 2024 | Volume: 52 | Issue: 11 | Pages: 1750-1767

10.1097/ccm.0000000000006418 | PMID 39417998 Get It

OBJECTIVES: Telecritical care (TCC) refers to the delivery of critical care using telehealth technologies. Despite increasing utilization, significant practice variation exists and literature regarding efficacy remains sparse. The Telecritical Care Collaborative Network sought to provide expert, consensus-based best practice recommendations for the design and delivery of TCC. DESIGN: We used a modified Delphi methodology. Following literature review, an oversight panel identified core domains and developed declarative statements for review by an expert voting panel. During three voting rounds, voters agreed or disagreed with statements and provided open-ended feedback, which the oversight panel used to revise statements. Statements met criteria for consensus when accepted by greater than or equal to 85% of voters. SETTING/SUBJECTS: The oversight panel included 18 multidisciplinary members of the TCC Collaborative Network, and the voting panel included 32 invited experts in TCC, emphasizing diversity of discipline, care delivery models, and geography. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: We identified ten core domains: definitions/terminology; care delivery models; staffing and coverage models; technological considerations; ergonomics and workplace safety; licensing, credentialing, and certification; trust and relationship building; quality, safety, and efficiency, research agenda; and advocacy, leading to 79 practice statements. Of 79 original statements, 67 were accepted in round 1. After revision, nine were accepted in round 2 and two in round 3 (two statements were merged). In total, 78 practice statements achieved expert consensus. CONCLUSIONS: These expert consensus recommendations cover a broad range of topics relevant to delivery of TCC. Experts agreed that TCC is most effective when delivered by care teams with specific expertise and by programs with explicit protocols focusing on effective communication, technical reliability, and real-time availability. Interventions should be tailored to local conditions. Although further research is needed to guide future best practice statements, these results provide valuable and actionable recommendations for the delivery of high-quality TCC.
Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201)
Jensen, Jeffrey L. , Bobek, Olivia , Chan, Irenaeus C.C. , Miller, Brian C. , Hillman, David W. , Heller, Glenn , Druley, Todd E. , Armstrong, Andrew J. , Morris, Michael J. , Milowsky, Matthew I. , Beltran, Himisha , Coombs, Catherine C. , Druley, Todd , Bolton, Kelly L , Coombs, Catherine C , Morris, Michael J , Hillman, David W , Heller, Glenn , Bobek, Olivia , Armstrong, Andrew J , Bolton, Kelly L.

Mayo Clinic

Clinical Cancer Research | September 17, 2024 | Volume: 30 | Issue: 21 | Pages: 4910-4919

10.1158/1078-0432.ccr-24-0803 | PMID 39287426 Get It

Abstract Purpose: Mutations in hematopoietic progenitor cells accumulate with age leading to clonal expansion, termed clonal hematopoiesis (CH). CH in the general population is associated with hematopoietic neoplasms and reduced overall survival (OS), predominantly through cardiovascular adverse events (CVAE). Because androgen receptor pathway inhibitors (ARPI) used in metastatic castration-resistant prostate cancer (mCRPC) are also associated with CVAEs and because CH negatively impacted survival in an advanced solid tumor cohort, we hypothesized that CH in mCRPC may be associated with increased CVAEs and inferior survival. Experimental Design: A targeted DNA sequencing panel captured common CH mutations in pretreatment blood samples from 957 patients enrolled in Alliance A031201: a randomized trial of enzalutamide ± abiraterone/prednisone in the first-line mCRPC setting. The primary outcome was the impact of CH on OS; the secondary outcomes were progression-free survival (PFS) and CVAEs. Results: Baseline comorbidities were similar by CH status. No differences in OS/progression-free survival were detected regardless of treatment arm or the variant allele frequency threshold used to define CH [primary: 2% (normal-CH, N-CH); exploratory: 0.5% (low-CH) and 10% (high-CH, H-CH)]. Patients with H-CH (7.2%) and TET2-mutated N-CH (6.0%) had greater odds of any CVAE (14.5% vs. 4.0%; P = 0.0004 and 12.3% vs. 4.2%; P = 0.010, respectively). More major CVAEs were observed in patients with H-CH (5.8% vs. 1.9%; P = 0.042) and N-CH (3.4% vs. 1.8%; P = 0.147). Conclusions: CH did not affect survival in patients with mCRPC treated with ARPIs in A031201. H-CH and TET2-mutated CH were associated with more CVAEs. These findings inform the risk/benefit discussion about ARPIs in mCRPC.
V-210.2: Pediatric to adult transition in solid organ transplant recipients: A systematic review of existing transition programs.
Yerigeri, Shivani , Pape, Lars, Johnson, Jonathan N. , Marks, Stephen D. , Twombley, Katherine , Doshi, Kush , Oh, Jun, Esquivel, Carlos O. , Raina, Rupesh, Twombley, Katherine E , Satariano, Matthew , McCulloch, Mignon , Raina, Rupesh

Mayo Clinic

Transplantation | September 16, 2024 | Volume: 108 | Issue: 9S | Pages: No page available

10.1097/01.tp.0001066744.48202.c5 Get It

Multi-Ingredient Pre-Workout Supplementation Does Not Influence Muscle Activation Following A Fatiguing Isokinetic Protocol
Connors, Benjamin R., Kowal, Rachel, Chomentowski, Peter J., Camic, Clayton L., Herring, Matthew, Kowal, Rachel, Sebastião, Émerson , Hill, Chris, Jagim, Andrew R.

Mayo Clinic

Medicine & Science in Sports & Exercise | September 16, 2024 | Volume: 56 | Issue: 10S | Pages: 506-507

10.1249/01.mss.0001056888.95100.aa Get It

Unplanned Excision of Synovial Sarcoma: Factors Associated with Recurrence and Survival
Broida, Samuel E. , Arguello, Alexandra M. , Sullivan, Mikaela H. , Okuno, Scott H. , Ho, Thanh P. , Rose, Peter S. , Xu‐Welliver, Meng , Houdek, Matthew T. , Okuno, Scott , Ho, Thanh P , Xu-Welliver, Meng , Houdek, Matthew T , Broida, Samuel E , Robinson, Steven I. , Siontis, Brittany L.

Mayo Clinic

Cancers | September 16, 2024 | Volume: 16 | Issue: 18 | Pages: 3157

10.3390/cancers16183157 | PMID 39335129 Get It

Background: Synovial sarcoma is rare and may present as a small, slow-growing mass. These tumors are often mistaken as benign and are therefore prone to unplanned and/or non-oncologic excision. We sought to identify the rate of unplanned excision of synovial sarcoma and risk factors for recurrence and survival among this cohort. Methods: The medical records of 246 patients evaluated at a single institution for synovial sarcoma between 1997 and 2022 were retrospectively reviewed. Of these, 87 (35%) underwent unplanned, non-oncologic excision. The mean age of the cohort was 49 years. Primary tumors were located in the extremity (n = 63), abdomen (n = 6), thorax (n = 7), head/neck (n = 8), and paraspinal region (n = 3). The median maximum pre-treatment dimension of the primary tumor was 4.8 cm (IQR 7–2.4). Seventy-seven (86%) patients underwent re-excision of the tumor bed, 39 (45%) received chemotherapy, and 63 (72%) received radiation therapy. Results: Among patients who underwent unplanned excision, local recurrence-free survival (LRFS) was 98% at 1 year and 82% at 5 years. Metastasis-free survival (MFS) was 91% at 1 year and 72% at 5 years. Disease-specific survival (DSS) was 98% at 1 year and 72% at 5 years. When adjusting for tumor size, tumors which underwent unplanned excision did not have worse recurrence or survival compared to those which had planned excision (p > 0.10). Size > 5 cm, monophasic subtype, and axial location were associated with increased risk of disease recurrence. Forty-six patients had residual tumor following re-excision, which was associated with worse MFS (HR 8.17, 95% CI [1.89, 35.2], p < 0.01) and DSS (HR 7.66, 95% CI [1.76, 33.4], p < 0.01). Patients who received radiotherapy had improved MFS (HR 6.4, 95% CI [1.42, 29.0], p = 0.02) and DSS (HR 5.86, 95% CI [1.27, 26.9], p = 0.02). Conclusions: One-third of patients presenting with synovial sarcoma were diagnosed after unplanned, non-oncologic excision. Patients with large, axial tumors had worse survival. Approximately half of patients who underwent unplanned excision had no residual tumor after pre-operative radiation. The use of radiation was associated with decreased rates of recurrence and improved disease-specific survival. Our results suggest that margin-negative re-resection and radiotherapy should be considered when feasible following unplanned excision of synovial sarcoma.
Visual assessments of 11C-Pittsburgh compound-B PET vs. 18F-flutemetamol PET across the age spectrum
Zeydan, Burcu , Przybelski, Scott A. , Lesnick, Timothy G. , Kantarci, Orhun H. , Min, Hoon‐Ki , Kemp, Bradley J. , Jack, Clifford R. , Kantarci, Kejal , Lowe, Val J. , Min, Hoon-Ki Paul , Jack, Clifford R , Kantarci, Kejal , Zeydan, Burcu , Johnson, Derek R. , Schwarz, Christopher G. , Senjem, Matthew L.

Mayo Clinic

Nuclear Medicine Communications | September 13, 2024 | Volume: 45 | Issue: 12 | Pages: 1047-1054

10.1097/mnm.0000000000001902 | PMID 39267525 Get It

Objective Visual assessments of amyloid-β PET, used for Alzheimer’s disease (AD) diagnosis and treatment evaluation, require a careful approach when different PET ligands are utilized. Because the gray matter (GM) and white matter (WM) ligand bindings vary with age, the objective was to investigate the agreement between visual reads of 11C- and 18F-PET scans. Methods Cognitively unimpaired (CU) younger adults (N = 30; 39.5 ± 6.0 years), CU older adults (N = 30; 68.6 ± 5.9 years), and adults with AD (N = 22; 67.0 ± 8.5 years) underwent brain MRI, 11C-Pittsburgh compound-B (PiB)-PET, and 18F-flutemetamol-PET. Amyloid-β deposition was assessed visually by two nuclear medicine specialists on 11C-PiB-PET and 18F-flutemetamol-PET, and quantitatively by PET centiloids. Results Seventy-two 11C-PiB-PET and 18F-flutemetamol-PET visual reads were concordant. However, 1 18F-flutemetamol-PET and 9 11C-PiB-PET were discordant with quantitative values. In four additional cases, while 11C-PiB-PET and 18F-flutemetamol-PET visual reads were concordant, they were discordant with quantitative values. Disagreements in CU younger adults were only with 11C-PiB-PET visual reads. The remaining disagreements were with CU older adults. Conclusion Age, GM/WM binding, amyloid-β load, and disease severity may affect visual assessments of PET ligands. Increase in WM binding with age causes a loss of contrast between GM and WM on 11C-PiB-PET, particularly in CU younger adults, leading to false positivity. In CU older adults, increased WM signal may bleed more into cortical regions, hiding subtle cortical uptake, especially with 18F-flutemetamol, whereas 11C-PiB can detect true regional positivity. Understanding these differences will improve patient care and treatment evaluation in clinic and clinical trials.
Cardiac Metastasis from Myxoid Liposarcoma Managed Successfully with Chemotherapy and Radiotherapy: Case Report and Review of the Literature
Stergiopoulos, Georgios M. , Petersen, Ivy A. , Houdek, Matthew T. , Ho, Thanh P. , Okuno, Scott H. , Houdek, Matthew T , Ho, Thanh P , Okuno, Scott , Siontis, Brittany L. , Robinson, Steven I.

Mayo Clinic

Current Oncology | September 12, 2024 | Volume: 31 | Issue: 9 | Pages: 5384-5398

10.3390/curroncol31090398 | PMID 39330026 Get It

Background: Liposarcoma, one of the most prevalent sarcoma histologies, is recognized for its tendency for extra-pulmonary metastases. While oligometastatic cardiac disease is rarely reported, it poses a unique challenge as oligometastatic sarcomas are often managed with surgical resection. Case Report: We present a case of a 62-year-old man diagnosed with an oligometastatic myxoid liposarcoma (MLPS) to the heart 19 years after the primary tumor resection from the lower limb. The metastatic mass, situated in the pericardium adjacent and infiltrating the left ventricle, was not managed surgically but with a combination of chemotherapy and radiotherapy. The patient’s disease remains stable to date, for more than 10 years. Literature Review: We conducted a review of the literature to determine the preferred management approach for solitary cardiac metastases of sarcomas. We also conducted an in-depth analysis focusing on reported cases of MLPS metastasizing to the heart, aiming to extract pertinent data regarding the patient characteristics and the corresponding management strategies. Conclusions: Although clinical diagnoses of solitary or oligometastatic cardiac metastases from sarcomas are infrequent, this case underscores the significance of aggressive management employing chemotherapy and radiotherapy for chemosensitive and radiosensitive sarcomas, especially when surgical removal is high-risk. Furthermore, it challenges the notion that surgery is the exclusive therapeutic option leading to long-term clinical benefit in patients with recurrent sarcomas.